Viatris Cash Flow from Financial Activities 2010-2024 | VTRS
Viatris annual/quarterly cash flow from financial activities history and growth rate from 2010 to 2024. Cash flow from financial activities can be defined as the net amount of cash transactions used in funding activities
- Viatris cash flow from financial activities for the quarter ending March 31, 2024 was $-0.426B, a 56.34% decline year-over-year.
- Viatris cash flow from financial activities for the twelve months ending March 31, 2024 was $-5.382B, a 41.43% decline year-over-year.
- Viatris annual cash flow from financial activities for 2023 was $-2.302B, a 40.64% decline from 2022.
- Viatris annual cash flow from financial activities for 2022 was $-3.878B, a 28.75% increase from 2021.
- Viatris annual cash flow from financial activities for 2021 was $-3.012B, a 397.28% increase from 2020.
| Viatris Annual Cash Flow Financial (Millions of US $) |
|
|---|---|
| 2023 | $-2,302 |
| 2022 | $-3,878 |
| 2021 | $-3,012 |
| 2020 | $-606 |
| 2019 | $-1,169 |
| 2018 | $-1,091 |
| 2017 | $-1,893 |
| 2016 | $5,345 |
| 2015 | $605 |
| 2014 | $-267 |
| 2013 | $693 |
| 2012 | $-612 |
| 2011 | $-645 |
| 2010 | $100 |
| 2009 | $-454 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $11.966B | $15.427B |
| Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $122.556B | 15.38 |
| Cencora (COR) | United States | $47.310B | 18.44 |
| ICON (ICLR) | Ireland | $26.285B | 24.82 |
| DiDi Global (DIDIY) | China | $21.823B | 0.00 |
| Avantor (AVTR) | United States | $14.665B | 21.59 |
| CochLear (CHEOY) | Australia | $14.459B | 0.00 |
| Natera (NTRA) | United States | $13.261B | 0.00 |
| Revvity (RVTY) | United States | $13.239B | 23.22 |
| Medpace Holdings (MEDP) | United States | $12.486B | 41.08 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $11.394B | 0.00 |
| Charles River Laboratories (CRL) | United States | $10.807B | 20.69 |
| Solventum (SOLV) | United States | $9.209B | 0.00 |
| Sonic Healthcare (SKHHY) | Australia | $8.426B | 0.00 |
| HealthEquity (HQY) | United States | $7.373B | 47.34 |
| Organon (OGN) | United States | $5.233B | 4.96 |
| Bausch + Lomb (BLCO) | Canada | $5.186B | 20.76 |
| Doximity (DOCS) | United States | $5.110B | 35.79 |
| PACS (PACS) | United States | $4.461B | 0.00 |
| Life Times (LTH) | United States | $3.655B | 38.29 |
| Sotera Health (SHC) | United States | $3.210B | 15.75 |
| Surgery Partners (SGRY) | United States | $3.184B | 29.13 |
| GoodRx Holdings (GDRX) | United States | $3.062B | 116.57 |
| Agilon Health (AGL) | United States | $2.772B | 0.00 |
| Progyny (PGNY) | United States | $2.450B | 42.18 |
| NovoCure (NVCR) | Jersey | $2.092B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $1.996B | 7.91 |
| Premier (PINC) | United States | $1.906B | 8.15 |
| BrightSpring Health Services (BTSG) | United States | $1.802B | 0.00 |
| Teladoc Health (TDOC) | United States | $1.711B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.566B | 0.00 |
| Alignment Healthcare (ALHC) | United States | $1.444B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.197B | 0.00 | |
| CareDx (CDNA) | United States | $0.733B | 0.00 |
| GeneDx Holdings (WGS) | United States | $0.721B | 0.00 |
| Embecta (EMBC) | United States | $0.719B | 4.89 |
| Pediatrix Medical (MD) | United States | $0.649B | 6.88 |
| Auna S.A (AUNA) | Luxembourg | $0.592B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.583B | 15.27 |
| InnovAge Holding (INNV) | United States | $0.575B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.440B | 0.00 |
| Enhabit (EHAB) | United States | $0.435B | 43.40 |
| ModivCare (MODV) | United States | $0.381B | 7.12 |
| Sonida Senior Living (SNDA) | United States | $0.379B | 0.00 |
| LifeMD (LFMD) | United States | $0.327B | 0.00 |
| DocGo (DCGO) | United States | $0.318B | 17.39 |
| Sharecare (SHCR) | United States | $0.290B | 0.00 |
| MultiPlan (MPLN) | United States | $0.246B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.237B | 0.00 |
| Beauty Health (SKIN) | United States | $0.223B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.189B | 0.00 |
| Biodesix (BDSX) | United States | $0.185B | 0.00 |
| So-Young (SY) | China | $0.107B | 51.51 |
| Pono Capital Two (PTWO) | United States | $0.071B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.048B | 0.00 |
| NeueHealth (NEUE) | United States | $0.044B | 5.88 |
| IceCure Medical (ICCM) | Israel | $0.036B | 0.00 |
| Oncology Institute (TOI) | United States | $0.030B | 0.00 |
| Nutex Health (NUTX) | United States | $0.027B | 0.00 |
| Singular Genomics Systems (OMIC) | United States | $0.024B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.023B | 0.00 |
| OncoCyte (OCX) | United States | $0.022B | 0.00 |
| KindlyMD (KDLY) | $0.016B | 0.00 | |
| BIMI Holdings (BIMI) | United States | $0.016B | 0.00 |
| TRxADE HEALTH (MEDS) | United States | $0.014B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.012B | 0.00 |
| XWELL (XWEL) | United States | $0.008B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.008B | 0.00 | |
| Intelligent Bio Solutions (INBS) | United States | $0.006B | 0.00 |
| ISpecimen (ISPC) | United States | $0.005B | 0.00 |
| DermTech (DMTK) | United States | $0.005B | 0.00 |
| NewGenIvf Group (NIVF) | Singapore | $0.003B | 0.00 |
| OpGen (OPGN) | United States | $0.003B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |
| Assure Holdings (IONM) | United States | $0.001B | 0.00 |